SCHEMBL10126440

SCHEMBL10126440

COc1cc(OC)c(CSc2ccc(O)cc2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.43
ABCB1 P08183 4/20 0.43
BCR P11274 4/20 0.43
APP P05067 1/20 0.41
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ALOX5 P09917 3/20 0.40
TTR P02766 2/20 0.40
CYP1A1 P04798 2/20 0.40
MAPK1 P28482 2/20 0.40
PTGS2 P35354 2/20 0.40
CYP1B1 Q16678 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NQO2 P16083 1/20 0.40
PTGS1 P23219 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8530817 0.75 EGFR (0.46) APPEGFRERBB2ALOX5KDM4E
SCHEMBL9475495 0.75 APP (0.70) APPNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL8529307 0.74 PTGS2 (0.50) PTGS2MAPTRAB9ACYP3A4SMN1; SMN2
SCHEMBL8529682 0.73 AKR1B1 (0.46) APPEGFRERBB2MAPK1MEN1
SCHEMBL995100 0.73 CD274 (0.47) ABL1ABCB1BCRCYP1A1CYP1B1
SCHEMBL2876753 0.73 ALDH1A1 (0.43) CYP1A1MAPK1CYP1B1MAPTUSP2
SCHEMBL24709121 0.71 NOS3 (0.43) CYP1A1CYP1B1CYP3A4
SCHEMBL2965027 0.71 ALDH1A1 (0.42) CYP1A1MAPK1CYP1B1USP2CYP3A4
SCHEMBL18844566 0.70 PTPN1 (0.39) MAPK1MAPTUSP2CYP3A4SMN1; SMN2
SCHEMBL3440588 0.70 ENPP2 (0.45) MEN1NPC1GAARAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807436-B1 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES INC (US) 2014-06-18 EP disclosed
US-20130178600-A1 POLY(ETHYLENE GLYCOL) DERIVATIVES FOR CLICK CHEMISTRY INTEZYNE TECHNOLOGIES, INC. (US) 2013-07-11 US disclosed
US-20130178600-A1 POLY(ETHYLENE GLYCOL) DERIVATIVES FOR CLICK CHEMISTRY INTEZYNE TECHNOLOGIES, INC. (US) 2013-07-11 US disclosed
EP-2502941-A1 Heterobifunctional poly (ethylene glycol) and uses thereof Intezyne Technologies Inc. (US) 2012-09-26 EP disclosed
US-8268936-B2 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-18 US disclosed
US-8268936-B2 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-18 US disclosed
US-20120226050-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-06 US disclosed
US-20120226050-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-06 US disclosed
US-8212083-B2 Use in PEGylation of biologicals; variety of terminal functional groups; made by polymerizing ethylene oxide on initiators such as N-(hydroxyalkyl) imines or N,N-bis(diphenyloxophosphino)-N-hydroxyalkylamines INTEZYNE TECHNOLOGIES, INC. (US) 2012-07-03 US disclosed
US-8212083-B2 Use in PEGylation of biologicals; variety of terminal functional groups; made by polymerizing ethylene oxide on initiators such as N-(hydroxyalkyl) imines or N,N-bis(diphenyloxophosphino)-N-hydroxyalkylamines INTEZYNE TECHNOLOGIES, INC. (US) 2012-07-03 US disclosed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 US disclosed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 US disclosed
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES (US) 2008-08-28 US disclosed
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES (US) 2008-08-28 US disclosed
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof INTEZYNE TECHNOLOGIES (US) 2008-08-07 US disclosed
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof INTEZYNE TECHNOLOGIES (US) 2008-08-07 US disclosed
WO-2007127440-A2 HETEROFUNCTIONAL POLY(ETHYLENE GLYCOL) CONTAINING ACID-LABILE AMINO PROTECTING GROUPS AND USES THEREOF INTEZYNE TECHNOLOGIES, INC. (US) 2007-11-08 WO disclosed
WO-2007127473-A2 POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188638-A1 Heterobifunctional poly(ethyleneglycol) containing acid-labile amino protecting groups and uses thereof LNPEP, GNE, DNPEP ABL1 264/4885ABCB1 2919/4885BCR 903/4885
US-20120226050-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS GNE, EPRS1, ALG1 ABL1 511/4885ABCB1 3298/4885BCR 224/4885
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups GNE, EPRS1, ALG1 ABL1 511/4885ABCB1 3298/4885BCR 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.